Advertisement

Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review

Published:September 05, 2022DOI:https://doi.org/10.1016/j.msard.2022.104157

      Highlights

      • We try to recommend the best treatment with the least side effects along with suitable effectiveness for Multiple Sclerosis (MS) patients.
      • This is the first systematic review to assess the post-marketing adverse effects of oral therapies (fingolimod, dimethylfumarat and teriflunomide) in multiple sclerosis.
      • The most side effects were observed with fingolimod and then teriflunomide, furthermore dimethylfumarat had the least side effects.

      Abstract

      Background

      There is a lack of safety information about the post-marketing adverse effects of several disease-modifying drugs (DMDs) used to control multiple sclerosis (MS). Investigating the post-marketing side effects is required to manifest the safety of the appropriate therapy. Therefore, the present systematic review aimed to identify disease-modifying drugs used to control multiple sclerosis attacks and progress.

      Methods

      The Web of Science, PubMed, and Scopus databases were searched for studies published until November 2020 based on the research strategy terms. Inclusion criteria involved all full texts exploring disease-modifying drugs used to control multiple sclerosis based on case reports and case series studies. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the quality of case report studies.

      Results

      In total, 25 articles that met the criteria for inclusion were retrieved in the present systematic review. The most side effects were observed with fingolimod and teriflunomide, respectively, while dimethyl fumarate had minor side effects.

      Conclusion

      The oral therapies have some significant post-marketing adverse effects that have been diagnosed in numerous case reports. Some of them are serious and must be noticed by neurologists. Accordingly, in this review, we assessed the post-marketing adverse effects of oral therapies for multiple sclerosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Agashivala N.
        • et al.
        Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
        BMC Neurol. 2013; 13: 1-9
        • Agirgol S.
        • et al.
        Psoriasiform eruption caused by teriflunomide in a patient with multiple sclerosis.
        Clin. Toxicol. 2019; 57: 1125-1127
        • Albrecht P.
        • et al.
        Effects of dimethyl fumarate on neuroprotection and immunomodulation.
        J. Neuroinflammation. 2012; 9: 1-10
        • Alroughani R.
        • et al.
        Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: an expert consensus narrative review.
        Mult. Scler. J. Exp. Transl. Clin. 2022; 820552173221077185
        • Ayers M.C.
        • Conway D.S.
        A case of presumed herpes keratouveitis in a patient treated with fingolimod.
        Mult. Scler. J. Exp. Transl. Clin. 2016; 22055217316652907
        • Azimi A.
        • et al.
        Effects of Vitamin D supplements on IL-10 and INFγ levels in patients with multiple sclerosis: a systematic review and meta-analysis.
        Maedica. 2019; 14: 413
        • Bar-Or A.
        • et al.
        Teriflunomide and its mechanism of action in multiple sclerosis.
        Drugs. 2014; 74: 659-674
        • Berger J.R.
        • et al.
        Progressive multifocal leukoencephalopathy after fingolimod treatment.
        Neurology. 2018; 90: e1815-e1821
        • Boiko A.
        • et al.
        Early onset multiple sclerosis: a longitudinal study.
        Neurology. 2002; 59: 1006-1010
        • Brinkmann V.
        FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system.
        Br. J. Pharmacol. 2009; 158: 1173-1182
        • Camara-Lemarroy C.R.
        • et al.
        Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: a case report.
        Mult. Scler. 2018; 24: 1383-1385
        • Chan A.
        • et al.
        Teriflunomide in patients with relapsing–remitting forms of multiple sclerosis.
        CNS Drugs. 2016; 30: 41-51
        • Chun J.
        • Hartung H.-P.
        Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
        Clin. Neuropharmacol. 2010; 33: 91
        • Cohen J.A.
        • et al.
        Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
        N. Engl. J. Med. 2010; 362: 402-415
        • Duquette A.
        • et al.
        Chronic diarrhea associated with high teriflunomide blood concentration.
        Rheumatol. Ther. 2016; 3: 179-185
        • Elounais F.
        • et al.
        Case report: ventricular tachycardia after initiation of fingolimod.
        BMJ Case Rep. 2017; : 2017
        • Feige J.
        • et al.
        Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
        Mult. Scler. Relat. Disord. 2020; 38101515
        • Ferreira C.M.
        • et al.
        Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: a case report.
        Medicine (Baltimore). 2021; 100
        • Foerch C.
        • et al.
        Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
        Mult. Scler. Relat. Disord. 2020; 42102180
        • Forrestel A.K.
        • et al.
        Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod.
        JAMA Neurol. 2016; 73: 355-356
        • Gerschenfeld G.
        • et al.
        Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
        Mult. Scler. 2015; 21: 1476-1477
        • Gold R.
        • et al.
        Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results.
        Mult. Scler. J. 2021; 13524585211037909
        • Hatcher S.E.
        • et al.
        Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment.
        JAMA Neurol. 2016; 73: 790-794
        • Hellmann M.
        • et al.
        Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
        J. Neurol. Sci. 2014; 344: 193-197
        • Kim W.
        • et al.
        Oral disease-modifying therapies for multiple sclerosis.
        J. Clin. Neurol. 2015; 11: 9-19
        • Klotz L.
        • et al.
        Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.
        Ther. Adv. Neurol. Disord. 2019; 121756286419836571
        • Landais A.
        • et al.
        A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
        Mult. Scler. Relat. Disord. 2017; 17: 92-94
        • Leypoldt F.
        • et al.
        Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
        Neurology. 2009; 72: 1022-1024
        • Li H.
        • et al.
        A review of possible therapies for multiple sclerosis.
        Mol. Cell. Biochem. 2021; 476: 3261-3270
        • Lorefice L.
        • et al.
        An unusual infection in MS patient treated with dimethyl fumarate: a case report of omphalitis.
        Mult. Scler. Relat. Disord. 2016; 7: 65-67
        • Ma L.-L.
        • et al.
        Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?.
        Military Med. Res. 2020; 7: 1-11
        • Mancinelli L.
        • et al.
        Nail loss after teriflunomide treatment: a new potential adverse event.
        Mult. Scler. Relat. Disord. 2017; 18: 170-172
        • Navardi S.
        • Sahraian M.A.
        A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
        Mult. Scler. Relat. Disord. 2018; 21: 69-70
        • Negrotto L.
        • Correale J.
        Palmar pustular psoriasis associated with teriflunomide treatment.
        Mult. Scler. Relat. Disord. 2019; 27: 400-402
        • Nitsan Z.
        • et al.
        Mycosis fungoides–A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
        J. Clin. Neurosci. 2018; 48: 102-103
        • O'Connor P.
        • et al.
        Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
        N. Engl. J. Med. 2011; 365: 1293-1303
        • O'Connor P.
        • et al.
        Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study.
        Neurology. 2016; 86: 920-930
        • Papathemeli D.
        • et al.
        Development of a primary cutaneous CD30 (+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
        Mult. Scler. 2016; 22: 1888-1890
        • Quintanilla-Bordás C.
        • et al.
        The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis.
        Transfusion (Paris). 2019; 59: 1648-1650
        • Rae-Grant A.
        • et al.
        Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
        Neurology. 2018; 90: 777-788
        • Son M.
        • et al.
        Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
        Mult. Scler. 2020; 26: 1801-1803
        • Tolou-Ghamari Z.
        • Mazdak H.
        Fingolimod for multiple sclerosis; mechanism of action, safety and toxicity.
        Arch. Neurosci. 2016; 3
        • Torkildsen Ø.
        • et al.
        Disease-modifying treatments for multiple sclerosis–a review of approved medications.
        Eur. J. Neurol. 2016; 23: 18-27
        • Turaka K.
        • Bryan J.S.
        Does fingolimod in multiple sclerosis patients cause macular edema?.
        J. Neurol. 2012; 259: 386-388
        • Vacchiano V.
        • et al.
        Teeth loss after teriflunomide treatment: casual or causal? A short case series.
        Mult. Scler. Relat. Disord. 2018; 24: 120-122
        • Verdugo R.M.
        • et al.
        Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain.
        Patient Prefer. Adherence. 2019; 13: 261
        • Warnke C.
        • et al.
        Review of teriflunomide and its potential in the treatment of multiple sclerosis.
        Neuropsychiatr. Dis. Treat. 2009; 5: 333
        • Zecca C.
        • et al.
        Life-threatening asthma attack during prolonged fingolimod treatment: case report.
        Patient Prefer. Adherence. 2014; 8: 987